These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

663 related items for PubMed ID: 17606705

  • 1. CCR drug updates: sorafenib and sunitinib in renal cell carcinoma.
    Stein MN, Flaherty KT.
    Clin Cancer Res; 2007 Jul 01; 13(13):3765-70. PubMed ID: 17606705
    [No Abstract] [Full Text] [Related]

  • 2. Therapy for metastatic RCC--questions remain.
    Breau RH, Leibovich BC.
    Nat Rev Urol; 2009 Nov 01; 6(11):580-1. PubMed ID: 19890336
    [No Abstract] [Full Text] [Related]

  • 3. Editorial comment.
    Vaishampayan U.
    Urology; 2010 May 01; 75(5):1114; author reply 1115. PubMed ID: 20451726
    [No Abstract] [Full Text] [Related]

  • 4. Editorial comment.
    Rini BI, Shah SN.
    Urology; 2010 May 01; 75(5):1114-5; author reply 1115. PubMed ID: 20451727
    [No Abstract] [Full Text] [Related]

  • 5. Two new drugs for renal cell carcinoma.
    Med Lett Drugs Ther; 2007 Feb 26; 49(1255):18-20. PubMed ID: 17325624
    [No Abstract] [Full Text] [Related]

  • 6. [New therapeutic regimes in metastasic renal-cell carcinoma].
    Bierer S, Hertle L, Nitschmann S.
    Internist (Berl); 2008 Jan 26; 49(1):114-7. PubMed ID: 18704353
    [No Abstract] [Full Text] [Related]

  • 7. Trials probe new agents for kidney cancer.
    Hampton T.
    JAMA; 2006 Jul 12; 296(2):155-7. PubMed ID: 16835411
    [No Abstract] [Full Text] [Related]

  • 8. Health policy: The UK 'postcode lottery' in renal cell carcinoma.
    Larkin J, Gore M.
    Nat Rev Urol; 2009 Dec 12; 6(12):636-8. PubMed ID: 19956190
    [No Abstract] [Full Text] [Related]

  • 9. [New drugs; sunitinib and sorafenib].
    van Bronswijk H, Dubois EA, Osanto S, Cohen AF.
    Ned Tijdschr Geneeskd; 2007 Dec 29; 151(52):2888-90. PubMed ID: 18257434
    [Abstract] [Full Text] [Related]

  • 10. [Interdisciplinary recommendations on targeted therapy in the treatment of renal cell carcinoma].
    Miller K, Bergmann L, Albers P, Jäger E, Jakse G, Geschwend JE, Marschner N.
    Aktuelle Urol; 2007 Jul 29; 38(4):328-30. PubMed ID: 17647172
    [Abstract] [Full Text] [Related]

  • 11. Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reports.
    Shaheen PE, Rini BI, Bukowski RM.
    Clin Genitourin Cancer; 2006 Jun 29; 5(1):78-81. PubMed ID: 16859583
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases.
    Desar IM, Mulder SF, Stillebroer AB, van Spronsen DJ, van der Graaf WT, Mulders PF, van Herpen CM.
    Acta Oncol; 2009 Jun 29; 48(6):927-31. PubMed ID: 19452305
    [No Abstract] [Full Text] [Related]

  • 15. [Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany].
    Bolenz C, Trojan L, Honeck P, Schöppler G, Herrmann E, Alken P, Michel MS, Häcker A.
    Aktuelle Urol; 2009 Jan 29; 40(1):31-6. PubMed ID: 19177319
    [Abstract] [Full Text] [Related]

  • 16. The loss of radiographic enhancement in primary renal cell carcinoma tumors following multitargeted receptor tyrosine kinase therapy is an additional indicator of response.
    Cowey CL, Fielding JR, Rathmell WK.
    Urology; 2010 May 29; 75(5):1108-13.e1. PubMed ID: 19931124
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Molecular targeted therapy for renal cell carcinoma].
    Kakehi Y.
    Rinsho Ketsueki; 2008 Aug 29; 49(8):622-5. PubMed ID: 18800611
    [No Abstract] [Full Text] [Related]

  • 19. Genetic basis of kidney cancer: a model for developing molecular-targeted therapies.
    Vira MA, Novakovic KR, Pinto PA, Linehan WM.
    BJU Int; 2007 May 29; 99(5 Pt B):1223-9. PubMed ID: 17441915
    [No Abstract] [Full Text] [Related]

  • 20. An update on the medical therapy of advanced metastatic renal cell carcinoma.
    Kruck S, Merseburger AS, Gakis G, Kramer MW, Stenzl A, Kuczyk MA.
    Scand J Urol Nephrol; 2008 May 29; 42(6):501-6. PubMed ID: 18615363
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.